Skip to main content

Table 3 Baseline variables associated with significant fibrosis (Fibroscan >7.9 kPa) among Ethiopian patients with chronic hepatitis B (n = 260)

From: Early experiences from one of the first treatment programs for chronic hepatitis B in sub-Saharan Africa

  No fibrosis N (%) Significant fibrosis N (%) Crude Adjusted
Baseline variable    OR (95% CI) P OR (95% CI) P
Gender
 Female 99 (53.2) 17 (23.0) 1   1  
 Male 87 (46.8) 57 (77.0) 3.8 (2.1–7.0) <0.001 3.0 (1.5–5.9) 0.002
Age group (years)
 18–25 41 (22.0) 12 (16.2) 1   1  
 26–35 92 (49.5) 23 (31.1) 0.9 (0.4–1.9) 0.695 1.5 (0.6–3.9) 0.406
 36–45 30 (16.1) 22 (29.7) 2.5 (1.1–5.8) 0.033 4.4 (1.5–12.8) 0.006
  > 45 23 (12.4) 17 (23.0) 2.5 (1.0–6.2) 0.043 3.6 (1.2–11.0) 0.022
Alcohol abuse
 No 184 (98.9) 71 (95.9) 1    
 Yes 2 (1.1) 3 (4.1) 3.9 (0.6–23.8) 0.142   
HBeAg (n = 255)
 Negative 174 (95.1) 60 (83.3) 1   1  
 Positive 9 (4.9) 12 (16.7) 3.9 (1.6–9.6) 0.004 2.7 (0.9–8.4) 0.087
HBV genotype (n = 68)
 A 38 (82.6) 19 (86.4) 1    
 D 8 (17.4) 3 (13.6) 0.8 (0.2–3.2) 0.695   
HDV co-infection (n = 259)
 No 180 (97.3) 72 (97.3) 1    
 Yes 5 (2.7) 2 (2.7) 1.0 (0.2–5.3) 1.000   
ALT (U/L)
  ≤ 40 166 (89.2) 56 (75.7) 1   1  
  > 40 20 (10.8) 18 (24.3) 2.7 (1.3–5.4) 0.006 1.8 (0.8–4.0) 0.162
HBV viral load (IU/ml) (n = 259)
  < 2000 114 (61.6) 37 (50.0) 1   1  
 2000–19,999 47 (25.4) 9 (12.2) 0.6 (0.3–1.3) 0.198 0.7 (0.3–1.6) 0.350
  ≥ 20,000 24 (13.0) 28 (37.8) 3.6 (1.9–7.0) <0.001 3.2 (1.4–7.4) 0.006
  1. OR odds ratio, CI confidence interval, HBeAg hepatitis B e-antigen, HBV hepatitis B virus, HDV hepatitis D virus, ALT alanine aminotransferase